中文摘要：

目的：探讨重组人血管内皮抑制素（恩度）联合肝动脉栓塞化疗术（TACE）治疗中晚期肝癌的临床疗效,为中晚期肝癌的临床治疗提供参考依据。方法：选择我院2012年6月至2013年7月收治的中晚期肝癌患者82例,根据治疗方法随机分为观察组（43例）和对照组（39例）,对照组给予TACE治疗;观察组在给予TACE治疗的基础上,联合恩度治疗。治疗结束后,观察和评价两组患者的临床疗效和不良反应的发生情况。结果：治疗后,观察组的有效率为46.51%（20/43）,显著高于对照组30.77%（12/39）（P〈0.05）;观察组的AFP水平为（412.58±10.66）μg/m L,明显低于对照组（445.27±11.39）μg/m L（P〈0.05）;两组并发症的发生率比较,差异无统计学意义（P〉0.05）。结论：恩度联合TACE治疗可以有效提高中晚期肝癌的临床疗效,且不增加不良反应。

英文摘要：

Objective： To explore the effect of Recombinant human endostatin（En Du） combined with transcatheter arterial chemoembolization（TACE） on medium and advanced liver cancer and provide the references for the clinical treatment of medium and advanced liver cancer. Methods： 83 patients with medium and advanced liver cancer admitted from June 2012 to July 2013 in our hospital were selected and divided into the control group（39 cases） and the intervention group（43 cases） by the treatment methods randomly. The patients of control group were treated with TACE, while the observation group was treated with TACE combined with Endu therapy. The clinical efficacy and incidence of adverse reactions were observed and compared between two groups after treatment.Results： The effective rate of the observation group was 46.51%（20/43）, which was OBVIOUSLY higher than that of the control group（30.77%, 12/39）（P0.05）; the serum AFP level of observation group was（412.58±10.66） μg/m L, which was significantly lower than that of the control group（445.27±11.39）μg/m L（P0.05）; No significant difference was found in the incidence rates of adverse reactions between two groups（P0.05）. Conclusion： Endu combined with TACE treatment could effectively improve the clinical efficacy of medium and advanced liver cancer.without more adverse reactions.